AZD1152 in Patients With Advanced Solid Malignancies-Study 3

This study has been terminated.
(Study is now terminated due to technical difficulties with administration of study drug in this patient population with this schedule)
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00497679
First received: July 5, 2007
Last updated: May 13, 2009
Last verified: May 2009

July 5, 2007
May 13, 2009
August 2006
Not Provided
Safety and Tolerability [ Time Frame: Assessed at each visit ]
Same as current
Complete list of historical versions of study NCT00497679 on ClinicalTrials.gov Archive Site
  • Pharmacokinetics [ Time Frame: Assessed at predetermined timepoints after dose administration ]
  • Effect on biomarkers [ Time Frame: Assessed after treatment ]
  • Anti-tumor activity [ Time Frame: Assessed at the end of treatment ]
Same as current
Not Provided
Not Provided
 
AZD1152 in Patients With Advanced Solid Malignancies-Study 3
A Phase I, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1152 Given as a Continuous 7-Day Intravenous Infusion in Patients With Advanced Solid Malignancies
The primary purpose of this protocol is to investigate the safety and tolerability of AZD1152 when given as a continuous 7-day infusion every week and every 2 weeks in patients with advanced solid malignancies.
Not Provided
Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Solid Tumours
Drug: AZD1152
7-day continuous intravenous infusion
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
45
July 2007
Not Provided

Inclusion Criteria:

  • Histological or cytological confirmation of a solid, malignant tumour

Exclusion Criteria:

  • Participation in an investigational drug study within 21 days prior to entry or who have not recovered from the effects of an investigational study drug
  • Treatment with radiotherapy/chemotherapy with 4 weeks of first dose
  • Recent major surgery within 4 weeks prior to entry to the study
Both
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United Kingdom
 
NCT00497679
D1531C00003, EudraCT: 2005-004244-31
No
Not Provided
Not Provided
Not Provided
AstraZeneca
Not Provided
Principal Investigator: David Kerr, MD University of Oxford
AstraZeneca
May 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP